Gembillo Guido, Sessa Concetto, Santoro Domenico
Unit of Nephrology and Dialysis, AOU "G. Martino", University of Messina, Messina 98125, Sicilia, Italy.
Unit of Nephrology and Dialysis, P.O. Maggiore "Nino Baglieri", Ragusa 97100, Sicilia, Italy.
World J Nephrol. 2025 Jun 25;14(2):103039. doi: 10.5527/wjn.v14.i2.103039.
Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular damage that significantly contributes to chronic kidney disease and end-stage renal disease. Its incidence is rising globally, necessitating timely and personalized management strategies. This paper aims to provide an updated overview of the pathophysiology, diagnosis, and therapeutic strategies for FSGS, emphasizing the importance of early interventions and tailored treatments. This editorial synthesizes key findings from recent literature to highlight advancements in understanding and managing FSGS. Emerging evidence supports the role of targeted therapies and personalized approaches in improving outcomes for FSGS patients. Advances include novel biomarkers, genetic testing, and innovative therapeutics such as transient receptor potential ion channel blockers and antisense oligonucleotides for apolipoprotein 1-related FSGS. Effective management of FSGS requires a combination of timely diagnosis, evidence-based therapeutic strategies, and ongoing research to optimize patient outcomes and address gaps in the current understanding of the disease.
局灶节段性肾小球硬化（FSGS）是一种肾小球损伤的组织学模式，对慢性肾脏病和终末期肾病有显著影响。其全球发病率正在上升，因此需要及时且个性化的管理策略。本文旨在提供FSGS病理生理学、诊断及治疗策略的最新综述，强调早期干预和个性化治疗的重要性。这篇社论综合了近期文献的关键发现，以突出在FSGS理解和管理方面的进展。新出现的证据支持靶向治疗和个性化方法在改善FSGS患者预后中的作用。进展包括新型生物标志物、基因检测以及诸如瞬时受体电位离子通道阻滞剂和载脂蛋白1相关FSGS的反义寡核苷酸等创新疗法。FSGS的有效管理需要及时诊断、基于证据的治疗策略以及持续研究相结合，以优化患者预后并填补当前对该疾病认识的空白。
